Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2024-01 Issue:1 Volume:11 Page:e38-e50
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Zeidan Amer M,Ando Kiyoshi,Rauzy Odile,Turgut Mehmet,Wang Ming-Chung,Cairoli Roberto,Hou Hsin-An,Kwong Yok-Lam,Arnan Montserrat,Meers Stef,Pullarkat Vinod,Santini Valeria,Malek Kamel,Kiertsman Flavia,Niolat Julie,Ramos Pedro Marques,Menssen Hans D,Fenaux Pierre,Miyazaki Yasushi,Platzbecker Uwe

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Hematology

Reference31 articles.

1. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Fenaux;Ann Oncol,2014

2. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data;Arber;Blood,2022

3. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms;Khoury;Leukemia,2022

4. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

5. Molecular international prognostic scoring system for myelodysplastic syndromes;Bernard;NEJM Evidence,2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Current challenges in conditioning regimens for MDS transplantation;Blood Reviews;2024-09

3. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment;Frontiers in Pharmacology;2024-08-05

4. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

5. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08